Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer.
Rakaee M, Tafavvoghi M, Ricciuti B, Alessi JV, Cortellini A, Citarella F, Nibid L, Perrone G, Adib E, Fulgenzi CAM, Murilo Hidalgo Filho C, Di Federico A, Jabar F, Hashemi S, Houda I, Richardsen E, Rasmussen Busund LT, Donnem T, Bahce I, Pinato DJ, Helland Å, Sholl LM, Awad MM, Kwiatkowski DJ. Rakaee M, et al. Among authors: adib e. JAMA Oncol. 2024 Dec 26. doi: 10.1001/jamaoncol.2024.5356. Online ahead of print. JAMA Oncol. 2024. PMID: 39724105
Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and Leukemia Volume 24, Issue 8, August 2024, Pages 523-530].
Lurain K, El Zarif T, Ramaswami R, Nassar AH, Adib E, Abdel-Wahab N, Chintapally N, Drolen CE, Feldman T, Haykal T, Nebhan CA, Kambhampati S, Li M, Mittra A, Lorentsen M, Kim C, Drakaki A, Morse M, Johnson DB, Mangla A, Dittus C, Ravi P, Baiocchi RA, Chiao EY, Rubinstein PG, Yellapragada SV, LaCasce AS, Sonpavde GP, Naqash AR, Herrera AF. Lurain K, et al. Among authors: adib e. Clin Lymphoma Myeloma Leuk. 2024 Dec;24(12):873. doi: 10.1016/j.clml.2024.10.011. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39603773 No abstract available.
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.
Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Nassar AH, et al. Among authors: adib e. J Thorac Oncol. 2024 Sep 10:S1556-0864(24)02265-2. doi: 10.1016/j.jtho.2024.09.1379. Online ahead of print. J Thorac Oncol. 2024. PMID: 39260522
Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer.
Skelton WP 4th, Masur J, Thomas J, Fallah P, Jain RK, Ravi P, Mantia C, McGregor BA, Nuzzo PV, Adib E, Zarif TE, Preston MA, Clinton TN, Li R, Steele GS, Kassouf W, Freeman D, Pond GR, Jain RK, Sonpavde GP. Skelton WP 4th, et al. Among authors: adib e. Clin Genitourin Cancer. 2024 Oct;22(5):102143. doi: 10.1016/j.clgc.2024.102143. Epub 2024 Jun 24. Clin Genitourin Cancer. 2024. PMID: 39032202
Response letter by Nassar et al.
Nassar AH, Kim SY, Adib E, Naqash AR, Goldberg SB. Nassar AH, et al. Among authors: adib e. J Thorac Oncol. 2024 May;19(5):e7-e8. doi: 10.1016/j.jtho.2024.03.013. J Thorac Oncol. 2024. PMID: 38719428 No abstract available.
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.
Lurain K, Zarif TE, Ramaswami R, Nassar AH, Adib E, Abdel-Wahab N, Chintapally N, Drolen CE, Feldman T, Haykal T, Nebhan CA, Thiruvengadam SK, Li M, Mittra A, Lorentsen M, Kim C, Drakaki A, Morse M, Johnson DB, Mangla A, Dittus C, Ravi P, Baiocchi RA, Chiao EY, Rubinstein PG, Yellapragada SV, LaCasce AS, Sonpavde GP, Naqash AR, Herrera AF. Lurain K, et al. Among authors: adib e. Clin Lymphoma Myeloma Leuk. 2024 Aug;24(8):523-530. doi: 10.1016/j.clml.2024.03.011. Epub 2024 Apr 5. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38714474
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.
Nassar AH, El Zarif T, Khalid AB, Rahme S, Zhong C, Kwak L, Salame M, Farhat EB, Freeman D, El-Am E, Ravishankar A, Ahmad B, Nana FA, Kaldas D, Naqash AR, Sharon E, LeBoeuf NR, Cortellini A, Malgeri A, Gupta S, Al-Hader A, Sparks JA, Linnoila J, Hamnvik OR, Mouhieddine TH, Marron T, Parikh K, McKay RR, Dilling T, Choueiri TK, Adib E, Najem E, Kim SY, Sonpavde G. Nassar AH, et al. Among authors: adib e. J Immunother Cancer. 2024 Mar 5;12(3):e008724. doi: 10.1136/jitc-2023-008724. J Immunother Cancer. 2024. PMID: 38448038 Free PMC article.
Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors.
Kerepesi C, Abushukair HM, Ricciuti B, Nassar AH, Adib E, Alessi JV, Pecci F, Rakaee M, Fadlullah MZH, Tőkés AM, Rodig SJ, Awad MM, Tan AC, Bakacs T, Naqash AR. Kerepesi C, et al. Among authors: adib e. JCO Precis Oncol. 2024 Feb;8:e2300439. doi: 10.1200/PO.23.00439. JCO Precis Oncol. 2024. PMID: 38330262
42 results